# Onvansertib

Source: https://onco.cc/drugs/onvansertib/  
OnCo record `onvansertib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Onvansertib is an oral serine/threonine kinase inhibitor from Cardiff Oncology, in registered phase 2 trials for colorectal cancer.

## Summary

Onvansertib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Cardiff Oncology, in colorectal cancer. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral serine/threonine kinase inhibitor
- Mechanism: A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family.

## Notes

- Onvansertib is an orally bioavailable, ATP-competitive inhibitor of polo-like kinase 1, which disrupts mitosis and causes G2/M arrest in PLK1-overexpressing cells (NCI Drug Dictionary).

## Sources

- ClinicalTrials.gov: trials of Onvansertib: https://clinicaltrials.gov/search?intr=Onvansertib
- NCI Drug Dictionary: onvansertib: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/onvansertib

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- targets: [PLK1](https://onco.cc/targets/plk1/)
- companies: [Cardiff Oncology](https://onco.cc/companies/cardiff-oncology/)
- trials: [Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer](https://onco.cc/trials/nct06736717/), [Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab fo](https://onco.cc/trials/nct06106308/), [Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer](https://onco.cc/trials/nct05450965/)

---
JSON: https://onco.cc/api/v1/entities/onvansertib.json